Therapy of Diabetes/HIV
Simplified Therapy of Diabetes/HIV
BROOKLYN, NY, KING'S COUNTY, USA, December 17, 2015 /EINPresswire.com/ -- Problem: Type 2 Diabetes and HIV/AIDS are the major cause of rise in healthcare cost. Currently, each disease is treated separately and require complex management.Statistics: In U.S. the National Healthcare Expenditure (NHE) is projected to hit $3.207 trillion this year averaging $ 10,000.00 per person. According to Center for Disease Control and Prevention (CDC), there are 1.2 Million patients with HIV in USA in 2012 above age 13 years. Meanwhile, diabetes number continue to escalate. There are now 29 million people with diabetes and 86 million patients with prediabetes.
Hypothesis: "Inflammation hypothesis" is gaining ground as the major cause of diabetes. Accelerated incidence of Diabetes in the presence of HIV/AIDS is a specific example to support this hypothesis. Standard therapies, don't target inflammation or its underlying cause in HIV/AIDS as well as in diabetes. This is driving up the cost of medical care. Advances in HIV therapies led to the global gains in drastically reducing mortality of millions of infected HIV people. They are living longer. HIV patients are at 11% or more at risk of developing Type 2 Diabetes with better antiviral drugs and weight gain.
Technology Advances: Endocrine Technology, L.L.C. detailed at www.etbondusa.com details a new patent application targeting inflammation as a common molecular target in HIV/AIDS and Type 2 diabetes.
Therapeutic Application: Endocrine Technology, L.L.C. has established an executive clinic detailed at www.etdiabetescenter.com that simplifies therapy of Type 2 diabetes using data analytic and latest advances.
Endocrine Technology, L.L.C. encourage and welcome patients with diabetes and HIV/AIDS to register at website: www.etdiabetescenter.com for the futuristic clinical trials and to obtain state of the art approved therapies.
Kumar Shah
Endocrine Technology, LLC
718-222-1065
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
